| Clinical data | |
|---|---|
| Trade names | Krystexxa, Puricase |
| AHFS/Drugs.com | Monograph |
| MedlinePlus | a611015 |
| License data |
|
| Routes of administration | Intravenous |
| Drug class | Urate oxidase[1] |
| Legal status | |
| Legal status |
|
| Pharmacokinetic data | |
| Bioavailability | N/A |
| Elimination half-life | 10–12 days |
| Chemical and physical data | |
| Formula | C1549H2430N408O448S8 (peptide monomer) |
| Molar mass | 497 kg/mol (polymer-modified tetramer) g·mol−1 |
  (what is this?) (verify) | |
Pegloticase, sold under the brand name Krystexxa, is a medication used to treat chronic gout.[1] It is a third line treatment in those in whom other treatments are not tolerated.[2] It is given by injection into a vein.[1]
Common side effects include worsening gout, pain at the site of injection, nausea, bruising, constipation, and anaphylaxis.[1] Other side effects may include worsening heart failure.[1] It should not be used in people with G6PD deficiency.[1] It is a manufactured form of the enzyme urate oxidase (uricase).[1]
Pegloticase was approved for medical use in the United States in 2010.[1] It was approved in 2013 in Europe but this was withdrawn in 2016.[3] In the United States it costs about 26,000 USD per dose.[4]
References edit
- ^ a b c d e f g h i j k "Pegloticase Monograph for Professionals". Drugs.com. Archived from the original on 5 August 2019. Retrieved 27 October 2021.
- ^ Dalbeth, N; Merriman, TR; Stamp, LK (22 October 2016). "Gout". Lancet. 388 (10055): 2039–2052. doi:10.1016/s0140-6736(16)00346-9. PMID 27112094. S2CID 208790780.
- ^ "Krystexxa Withdrawal of the marketing authorisation in the European Union" (PDF). Archived (PDF) from the original on 26 March 2017. Retrieved 25 March 2017.
- ^ "Krystexxa Prices, Coupons & Patient Assistance Programs". Drugs.com. Archived from the original on 26 January 2021. Retrieved 27 October 2021.